Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin for MDD
NCT00570050Phase 3Completed
- Sponsor
- University Health Network
- Start
- Jun 2013
- Primary completion
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Generex Oral-lyn in major depressive disorder (MDD) (2 arms), sponsored by University Health Network. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 9 weeks. Started Jun 2013; status: completed.
02
Drugs
Generex Oral-lyn
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00570050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570050.